Clinical Trials
11 trialsNCT04589728 2025-07-08
Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96
Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed
NCT06390306 2025-06-03
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Peking University People's Hospital
Recruiting
NCT06993883 2025-05-29
AML
Sohag University
Completed
NCT04282811 2025-01-17
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting
NCT03873857 2023-09-01
FORTE
AbbVie
Completed
NCT04230564 2023-06-07
Acute Myeloid Leukemia Real World Treatment Patterns
Pfizer
Withdrawn
NCT05312112 2023-03-02
Real World Outcomes Using Novel Agents for AML in the UK
Guy's and St Thomas' NHS Foundation Trust
Unknown
NCT04613622 2021-10-28
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia
National Taiwan University Hospital
Unknown
NCT04616274 2021-10-28
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
National Taiwan University Hospital
Unknown
NCT03662724 2021-02-16
VENreg
Hannover Medical School
Unknown
NCT04454580 2020-09-16
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Ospedale Maggiore Di Trieste
Unknown